Development of 7HP349, an oral integrin activator to enhance therapeutic responses to immune checkpoint inhibitors
Ended Project Grant Awarded Last action
- Award ID
- R44CA250646
- Recipient
-
7 Hills Pharma Inc. UEI CJJ6DE7APKY6
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,031,182
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Funding
-
- $3,015,591.00 Federal
- $1,015,591.00 Non-federal
- Place of performance
- Texas, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $1,015,591 | $0 | |
| Amendment | $1,015,591 | $1,015,591 | |
| Original award | $984,409 | $0 |
Quick answers
Who received award R44CA250646?
R44CA250646 was awarded to 7 Hills Pharma Inc. by National Cancer Institute (National Institutes of Health) on September 11, 2020.
How much is award R44CA250646 worth?
$4,031,182 has been obligated on R44CA250646: $3,015,591 in federal funding and $1,015,591 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award